Flash Finance

Morepen Laboratories LimitedMOREPENLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹123.87
MCap ₹6,788 Cr · P/E 48.0
Morepen Laboratories Limited — Stock analysis & AI research Morepen Laboratories Limited — Multibagger AI analysis Morepen Laboratories Limited — Seasonality — best & worst months Morepen Laboratories Limited — Technical indicators & charts Morepen Laboratories Limited — Technical setup — score, trend, support & resistance Morepen Laboratories Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results 📈 MACD Bearish Crossover📈 SuperTrend Bearish Signal📈 Relative Strength Leaders📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹570 Cr
Sales · Jun 2026
+34.1% YoY
₹83 Cr
Operating Profit · Jun 2026
+241.5% YoY
14.5%
OPM % · Jun 2026
+154.4% YoY
₹56 Cr
Net Profit · Jun 2026
+394.0% YoY
₹1.03
EPS · Jun 2026
+415.0% YoY

📝 Morepen Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Morepen Laboratories Limited reported revenue of ₹570 crore for the quarter ended June 2026 (Q1 FY27), up 34.1% from ₹425 crore in the same quarter last year, and up 17.6% sequentially over the March 2026 quarter.

Net profit rose 394.0% year-on-year to ₹56 crore, from ₹11 crore. Earnings per share (EPS) came in at ₹1.03.

Operating profit stood at ₹83 crore — an operating margin (OPM) of 14.5%, compared with 5.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Morepen Laboratories Limited posted revenue of ₹1,806 crore, a decline of 0.3% over FY25, with a net profit of ₹96 crore (down 18.3% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,951 crore with a net profit of ₹141 crore.

Valuation snapshot

At the current price of ₹123.87, MOREPENLAB has a market capitalisation of ₹6,788 crore and a trailing P/E of about 48.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 7th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 3.43%, domestic institutional investors (DIIs) 1.71%, the government 0.01%, public shareholders 59.19% of Morepen Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹6,788 Cr
Current Price ?
₹123.9
P/E ?
48.01above ind
Industry P/E ?
37.20
P/B ?
5.44
P/S ?
3.48
P/FCF ?
-53.44
Enterprise Value ?
₹6,996 Cr
EV/EBITDA ?
38.18
PEG ?
2.00
Earnings Yield ?
2.1%
Dividend Yield ?
0.38%
Profitability & Returns
Sales (TTM) ?
₹1,951 Cr
OPM ?
9.4%
Profit after tax (TTM) ?
₹141 Cr
EPS (TTM) ?
₹2.58
ROCE ?
8.0%
ROE ?
11.3%
ROA ?
7.3%
Growth
Sales — latest qtr ?
₹570 Cr
PAT — latest qtr ?
₹56 Cr
YoY qtr sales growth ?
34.1%
YoY qtr profit growth ?
394.0%
Sales growth (3y) ?
8%
Sales growth (5y) ?
9%
Profit growth (3y) ?
24%
Profit growth (5y) ?
-5%
Financial Health
Debt ?
₹208 Cr
Debt to Equity ?
0.17
Interest Coverage ?
5.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
35.65%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
110.3%
Return 6 months ?
195.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 348364401422445423455438453466425412484485570 +34.1% +17.6%
Operating Profit 211626345148524436422431462483 +241.5% +243.9%
Other Income 132344355545485 +17.6% -35.2%
Interest 110021111544445 +19.9% +21.0%
Depreciation 7788810625169111068 -7.5% +39.1%
Profit Before Tax 141121294442484635261646352375 +380.3% +224.0%
Net Profit 9815213229363527201141281656 +394.0% +252.2%
EPS 0.150.160.290.420.630.540.710.650.490.350.200.750.500.291.03 +415.0% +255.2%
OPM % 5.9% 4.3% 6.5% 8.1% 11.4% 11.4% 11.3% 10.1% 8.0% 9.1% 5.7% 7.5% 9.5% 4.9% 14.5% +154.4% +195.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,812 Cr ₹1,806 Cr ₹1,951 Cr -0.3%
Operating Profit ₹174 Cr ₹125 Cr ₹183 Cr -28.3%
OPM % 9.61% 6.91% 9.39% -28.1%
NPM % 6.51% 5.34% 7.25% -18.0%
Other Income ₹18 Cr ₹21 Cr ₹22 Cr +14.6%
Depreciation ₹29 Cr ₹36 Cr ₹36 Cr +25.3%
Interest ₹8 Cr ₹16 Cr ₹17 Cr +94.5%
EBIT ₹145 Cr ₹89 Cr ₹148 Cr -39.0%
PBT ₹155 Cr ₹119 Cr ₹178 Cr -23.1%
Tax ₹37 Cr ₹9 Cr ₹23 Cr -76.4%
Net Profit ₹118 Cr ₹96 Cr ₹141 Cr -18.3%
EPS ₹2.20 ₹1.74 ₹2.57 -20.9%
Material Cost ₹1,206 Cr ₹507 Cr ₹591 Cr -57.9%
Employee Cost ₹209 Cr ₹112 Cr ₹119 Cr -46.4%
Extraordinary Items — ₹26 Cr ₹26 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 102102110110 +0.0%
Reserves 6517451,0471,137 +8.6%
Borrowings 2529105208 +98.1%
Other Liabilities 332417517482 -6.8%
Total Liabilities 1,1101,2931,7781,936 +8.9%
Fixed Assets 267307489513 +4.9%
CWIP 17242822 -21.4%
Investments 0185124 +45.9%
Other Assets 8279601,1761,277 +8.6%
Total Assets 1,1101,2931,7781,936 +8.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -91733233 +3.1%
Cash from Investing Activity -47-83-322-123 +61.8%
Cash from Financing Activity 144530097 -67.7%
Net Cash Flow 6-5107 -30.0%
Free Cash Flow -137-8-182-127 +30.2%
CFO/OP -94%70%40%46% +15.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 68706567 +3.1%
Inventory Days 87859488 -6.4%
Days Payable 87101114103 -9.6%
Cash Conversion Cycle 69544553 +17.8%
Working Capital Days 9894107122 +14.0%
ROCE % 8%17%15%8% -46.7%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 35.66%35.66%35.66%35.66%35.65% -0.0%
FIIs 1.72%1.62%1.62%1.59%3.43% +115.7%
DIIs 1.50%1.49%1.25%1.25%1.71% +36.8%
Government 0.01%0.01%0.01%0.01%0.01% +0.0%
Public 61.09%61.22%61.46%61.50%59.19% -3.8%
No. of Shareholders 4,61,1804,61,8534,53,1374,47,2864,03,932 -9.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Morepen Laboratories Limited's revenue in Q1 FY27?
Morepen Laboratories Limited reported revenue of ₹570 crore for the quarter ended June 2026 (Q1 FY27), up 34.1% from ₹425 crore in the same quarter last year, and up 17.6% sequentially over the March 2026 quarter.
What was Morepen Laboratories Limited's net profit in Q1 FY27?
Net profit rose 394.0% year-on-year to ₹56 crore, from ₹11 crore. Earnings per share (EPS) came in at ₹1.03.
What is MOREPENLAB's market capitalisation and P/E ratio?
At the current price of ₹123.87, MOREPENLAB has a market capitalisation of ₹6,788 crore and a trailing P/E of about 48.0.
Who owns Morepen Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 3.43%, domestic institutional investors (DIIs) 1.71%, the government 0.01%, public shareholders 59.19% of Morepen Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI